SYNLAB Future Growth
Future criteria checks 0/6
SYNLAB is forecast to grow revenue at 2.8% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Healthcare earnings growth | 23.3% |
Revenue growth rate | 2.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 28 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 2,742 | N/A | 45 | 148 | 1 |
12/31/2024 | 2,634 | N/A | -21 | 162 | 1 |
3/31/2024 | 2,615 | 89 | 296 | 419 | N/A |
12/31/2023 | 2,635 | 92 | 237 | 363 | N/A |
9/30/2023 | 2,691 | 129 | 138 | 303 | N/A |
6/30/2023 | 2,772 | 69 | 216 | 374 | N/A |
3/31/2023 | 2,892 | -37 | 305 | 461 | N/A |
12/31/2022 | 3,251 | 151 | 471 | 630 | N/A |
9/30/2022 | 3,542 | 345 | 614 | 774 | N/A |
6/30/2022 | 3,693 | 404 | 714 | 872 | N/A |
3/31/2022 | 3,888 | 653 | 848 | 1,001 | N/A |
12/31/2021 | 3,765 | 608 | 867 | 1,012 | N/A |
9/30/2021 | 3,703 | 591 | 965 | 1,085 | N/A |
6/30/2021 | 3,561 | 385 | 816 | 929 | N/A |
3/31/2021 | 3,080 | 225 | 590 | 692 | N/A |
12/31/2020 | 2,621 | 36 | 426 | 520 | N/A |
12/31/2019 | 1,906 | -122 | 289 | 360 | N/A |
12/31/2018 | 1,808 | -51 | 253 | 339 | N/A |
12/31/2017 | 1,817 | -166 | N/A | 213 | N/A |
12/31/2016 | 1,570 | -230 | N/A | 232 | N/A |
12/31/2015 | 845 | -169 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 0A9B's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if 0A9B's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if 0A9B's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 0A9B's revenue (2.8% per year) is forecast to grow slower than the UK market (3.6% per year).
High Growth Revenue: 0A9B's revenue (2.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0A9B's Return on Equity is forecast to be high in 3 years time